Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer

Prostate cancer (PCa) accounted for over 300 000 deaths world-wide in 2018. Most of the PCa deaths occurred due to the aggressive castration-resistant PCa (CRPC). Since the androgen receptor (AR) and its ligands contribute to the continued growth of androgen-dependent PCa (ADPCa) and CRPC, AR has be...

Full description

Bibliographic Details
Main Author: Ramesh Narayanan
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:Asian Journal of Urology
Subjects:
Androgen receptor (AR)
AR variants
Prostate cancer
AR antagonists
AR ligand binding domain
AR activation function-1 domain
Online Access:http://www.sciencedirect.com/science/article/pii/S2214388220300230

Internet

http://www.sciencedirect.com/science/article/pii/S2214388220300230

Similar Items